At-home Management of Food-induced Anaphylaxis
DOI:
https://doi.org/10.58931/cait.2024.4375Abstract
Anaphylaxis is an acute, potentially life-threatening, systemic reaction characterized by the involvement of two or more body systems. The National Institute of Allergy and Infectious Diseases and Food Allergy and Anaphylaxis Network (NIAID/FAAN) have well-established criteria for the clinical definition of anaphylaxis. Anaphylaxis is a severe allergic reaction that occurs suddenly after contact with an allergy-causing substance (e.g., peanuts), insect venom or medications (e.g., antibiotics). Anaphylaxis criteria include an acute onset of symptoms (within minutes to several hours) involving the skin, mucosal tissue, or both, which may present with generalized hives, pruritus or flushing, or swollen lips, tongue, and uvula. In addition, one or more of the following must be present: respiratory compromise, reduced blood pressure, or associated symptoms of end-organ dysfunction. Anaphylaxis results in a sudden release of mediators, including, but not limited to, histamine from activated mast cells and basophils following the cross-linking of specific immunoglobulin E. Together with downstream mediators, such as prostaglandin D2, platelet activating factor, and leukotrienes, this reaction manifests clinically through peripheral vasodilation, bronchoconstriction, and increased vascular permeability, presenting as a multi-organ emergency requiring immediate intervention.
It is estimated that up to 5% of the population has experienced anaphylaxis, although fatality rates are very low at approximately 0.3% and occur most commonly with drug-induced anaphylaxis. Older age, often consistent with pre-existing comorbidities, and delayed epinephrine administration, pose the most significant risk factors for anaphylaxis fatality. While the global rates of anaphylaxis appear to be on the rise, case fatalities fortunately do not seem to follow this trend.
References
Anaphylaxis | Allergy & Asthma Network [Internet]. [cited 2024 Sep 10]. Available from: https://allergyasthmanetwork.org/anaphylaxis/
Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006 Feb;117(2):391-7.
Peavy RD, Metcalfe DD. Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol. 2008 Aug;8(4):310-5.
Turner PJ, Jerschow E, Umasunthar T, et al. Fatal anaphylaxis: mortality rate and risk factors. J Allergy Clin Immunol Pract. 2017;5(5):1169-78.
Shaker M, Abrams EM, Greenhawt M. A cost-effectiveness evaluation of hospitalizations, fatalities, and economic outcomes associated with universal versus anaphylaxis risk-stratified COVID-19 vaccination strategies. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2658-68.e3.
Turner PJ, Campbell DE, Motosue MS, et al. Global trends in anaphylaxis epidemiology and clinical implications. J Allergy Clin Immunol Pract. 2020 Apr;8(4):1169-76.
Dribin TE, Castells M. Anaphylaxis. Immunol Allergy Clin North Am. 2022 Feb;42(1):187-200.
Dribin TE, Sampson HA, Camargo CA, et al. Persistent, refractory, and biphasic anaphylaxis: A multidisciplinary Delphi study. J Allergy Clin Immunol. 2020 Nov;146(5):1089-96.
Ichikawa M, Kuriyama A, Urushidani S, et al. Incidence and timing of biphasic anaphylactic reactions: a retrospective cohort study. Acute Med Surg. 2021 Jul 30;8(1):e689.
Kraft M, Scherer Hofmeier K, et al. Risk factors and characteristics of biphasic anaphylaxis. J Allergy Clin Immunol: In Practice. 2020 Nov 1;8(10):3388-95.e6.
Ellis AK, Day JH. Incidence and characteristics of biphasic anaphylaxis: a prospective evaluation of 103 patients. Ann Allergy Asthma Immunol. 2007 Jan 1;98(1):64-9.
Alqurashi W, Stiell I, Chan K, et al. Epidemiology and clinical predictors of biphasic reactions in children with anaphylaxis. Ann Allergy Asthma Immunol. 2015 Sep;115(3):217-23.e2.
Navalpakam A, Thanaputkaiporn N, Poowuttikul P. Management of anaphylaxis. Immunol Allergy Clin North Am. 2022 Feb 1;42(1):65-76.
Ellis AK. Priority role of epinephrine in anaphylaxis further underscored—the impact on biphasic anaphylaxis. Ann Allergy Asthma Immunol. 2015 Sep 1;115(3):165.
Chooniedass R, Temple B, Becker A. Epinephrine use for anaphylaxis: Too seldom, too late. Ann Allergy Asthma Immunol. 2017 Aug;119(2):108-10.
Dodd A, Hughes A, Sargant N, et al. Evidence update for the treatment of anaphylaxis. Resuscitation. 2021 Jun;163:86-96.
Tal Y, Ribak Y, Rubin L, et al. Fast acting, dry powder, needle-free, intranasal epinephrine spray: a promising future treatment for anaphylaxis. J Allergy Clin Immunol: In Practice. 2023 Oct 1;11(10):3047-54.
Eurneffy | European Medicines Agency (EMA) [Internet]. 2024 [cited 2024 Sep 10]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/eurneffy
Commissioner O of the. FDA. FDA; 2024 [cited 2024 Sep 10]. FDA Approves First Nasal Spray for Treatment of Anaphylaxis. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-nasal-spray-treatment-anaphylaxis
Casale TB, Wang J, Nowak-Wegrzyn A. Acute at home management of anaphylaxis during the Covid-19 pandemic. J Allergy Clin Immunol Pract. 2020 Jun;8(6):1795-7.
Casale TB, Wang J, Oppenheimer J, et al. Acute at-home management of anaphylaxis: 911: what Is the emergency? J Allergy Clin Immunol Pract. 2022 Sep;10(9):2274-9.
Dribin TE, Waserman S, Turner PJ. Who needs epinephrine? Anaphylaxis, autoinjectors, and parachutes. J Allergy Clin Immunol Pract. 2023 Apr;11(4):1036-46.
Greenhawt M, Lieberman JA, Dribin TE, et al. Retire the advice to send patients to the emergency department after epinephrine use for observation. Ann Allergy Asthma Immunol. 2023 Jun;130(6):697-8.
Considerations for at-home management of food-induced anaphylaxis [Internet]. CSACI. [cited 2024 Sep 8]. Available from: https://www.csaci.ca/considerations-for-at-home-management-of-food-induced-anaphylaxis/
Golden DBK, Wang J, Waserman S, et al. Anaphylaxis: A 2023 practice parameter update. Ann Allergy Asthma Immunol. 2024;132(2):124-176. doi:10.1016/j.anai.2023.09.015
Alqurashi W, Ellis AK. Do corticosteroids prevent biphasic anaphylaxis? J Allergy Clin Immunol Pract. 2017;5(5):1194-205.
Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and grading of recommendations, assessment, development and evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020 Apr;145(4):1082-1123.
Pourmand A, Robinson C, Syed W, et al. Biphasic anaphylaxis: A review of the literature and implications for emergency management. Am J Emerg Med. 2018 Aug;36(8):1480-5.
Warren CM, Zaslavsky JM, Kan K, et al. Epinephrine auto-injector carriage and use practices among US children, adolescents, and adults. Ann Allergy Asthma Immunol. 2018 Oct;121(4):479-489.e2.
Turner PJ, Arasi S, Ballmer-Weber B, et al. Risk factors for severe reactions in food allergy: Rapid evidence review with meta-analysis. Allergy. 2022 Sep;77(9):2634-52.
Nurmatov U, Worth A, Sheikh A. Anaphylaxis management plans for the acute and long-term management of anaphylaxis: a systematic review. J Allergy Clin Immunol. 2008 Aug;122(2):353-61, 361.e1-3.